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been investigated in the past.
Aim: The objective of this study was to assess the relative contribution of a wider 




history	 of	 neuropathies,	 current/past	 infectious	 diseases;	 neurotoxic	 medication	










symptom	burden	 (OR	=	1.06,	p	 <	0.05),	 number	of	 chemotherapy	 cycles	 received	
(OR	=	1.19–1.24,	p	<	0.01),	 and	alcohol	 intake	 (OR	=	0.32,	p	<	0.05).	 In	univariate	
analysis,	the	use	of	statins	was	implicated	with	CIPN	(p	=	0.03–0.04	with	different	
assessments)	and	diabetes	showed	a	trend	(p	=	0.09)	in	the	development	of	CIPN.












tion for developing CIPN is observed in nerves previously damaged 
by	 diabetes	 mellitus,	 alcohol,	 or	 inherited	 neuropathy	 (Quasthoff	









Research around risk factors for CIPN has increased over re‐
cent	years,	although	at	times	findings	are	inconsistent	or	a	limited	
pool	of	potential	 factors	 is	assessed.	 In	a	 large	study	 (n	=	3,106),	







lative	 dose	 of	 chemotherapy,	 and	 poorer	 functional	 status	 were	




not	 been	 fully	 investigated	 to	date.	Hence,	 the	 aim	of	 this	 study	
was to assess the relative contribution of a wider range of risk fac‐
tors	in	the	development	of	CIPN,	providing	a	stronger	explanatory	
model,	 and	 further	 explore	 the	 potential	 link	 between	CIPN	 and	
other symptoms.
2  | MATERIAL S AND METHODS
2.1 | Design
This	 analysis	 used	 data	 from	 the	 6‐month	 CIPN	 assessment	 after	
starting chemotherapy from a larger prospective observational 
study	 on	 CIPN	 prevalence	 and	 quality	 of	 life	 (Molassiotis	 et	 al.,	
2019),	focusing	on	one	of	the	primary	objectives	of	the	study.
2.2 | Sample and settings
The	 sample	 included	 patients	 receiving	 platinum‐based	 chemo‐
therapy	 (primarily	 cisplatin)	 and	 taxane‐based	 chemotherapy	
(primarily	 docetaxel)	 for	 the	 treatment	 of	 breast,	 lung,	 ovarian,	
gastrointestinal,	head	&	neck	as	well	as	urinary	tract	cancers.	Data	
were collected from specialist oncology clinics in three countries/
regions	 (Hong	 Kong,	 Singapore,	 and	Manchester	 in	 the	 UK).	 The	
study	was	 approved	 by	 the	 ethics	 committees	 of	 the	Hong	 Kong	
Polytechnic	University,	Hong	Kong;	Central	Cluster	of	the	Hospital	
Authority,	Hong	Kong;	The	National	University	Hospital;	Singapore;	
The	 University	 of	 Manchester,	 Manchester,	 UK;	 and	 the	 Central	
Manchester	Research	and	Ethics	Committee.	All	participants	have	
provided written informed consent.
3  | PROCEDURES
Eligible patients were identified and approached at hospital out‐
patients clinics. Those who agreed to participate and provided in‐
formed signed consent completed all the baseline measurements 
including personal characteristics and presence of potential risk fac‐
tors as identified in the literature. Clinical data were obtained from 
the medical records as well as information on medication used and 
past medical history. Participants in the larger project underwent 
a neuropathy assessment repeated at each cycle of chemotherapy 
(up	 to	 six	 cycles),	 6	months,	 9	months,	 and	12	months	postchem‐
otherapy.	For	 the	current	analysis,	data	 from	 the	6‐month	assess‐
ment were used as it had the highest number of patients across all 
Conclusion: This study confirmed the CIPN risk related to certain variables and iden‐
tified new ones. This knowledge can assist with treatment decisions and patient 
education.
K E Y W O R D S
cancer,	chemotherapy‐induced	peripheral	neuropathy,	platinum	chemotherapy,	risk	factors,	
taxanes
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assessments and the highest incidence of CIPN. Ethical approval was 
obtained from each site before commencing the study.






•	 Diagnosis	with	 acquired	 or	 hereditary	 neuropathy	 such	 as	 dia‐
betes,	 renal	disease,	hypothyroidism,	connective	tissue	disease.	
Prior history of neuropathy or family history of neuropathy; vi‐
tamin	deficiencies	(Hershman	et	al.,	2016;	Ottaiano	et	al.,	2016;	
Seretny	et	al.,	2014).
•	 Diagnosis	 with	 current	 or	 previous	 infectious	 diseases	 (HIV;	
Poliomyelitis;	Hepatitis	B	or	C;	Armstrong	et	 al.,	2005;	Kaley	&	
DeAngelis,	2009;	Seretny	et	al.,	2014).









combination	 of	 taxanes	 and	 platinum‐based	 chemotherapy),	
number	 of	 chemotherapy	 cycles,	 and	 cumulative	 dosage	 of	
each	 neurotoxic	 chemotherapy	 drug	 (Kaley	 &	 DeAngelis,	
2009;	Quasthoff	&	Hartung,	2002;	Simon	et	al.,	2017).









for	 Adverse	 Events	 (NCI‐CTCAE)	 version	 4.03	 is	 a	 physician‐
rated grading system that includes criteria and definitions for 
quantifying	 and	 grading	 CIPN.	 This	 grading	 scale	 comprises	
two	 items,	with	a	sensory	and	a	motor	assessment	and	utilizes	
a	 5‐point	 scale	 ranging	 from	 grade	 1	 to	 grade	 5.
2.	 The	WHO	criterion	 is	also	a	physician‐rated	CIPN	 item,	and	 in‐
cludes	paresthesia,	reflex	decreases	and	extend	of	motor	loss	as	
parameters	(WHO,	1979).



























Descriptive	 statistics	 were	 used	 to	 summarize	 the	 data.	 Chi‐square	
analysis assessed differences in categorical variables while Student's t 
tests	were	used	for	comparing	continuous	variables.	Logistic	regression	
models were used for the main risk factor analysis. The relevant covari‐




portant covariates so that a more manageable set of variables can be 
used	with	more	complex	multivariate	statistical	techniques	(Lee,	2014).	





Data	 from	 255	 participants	 were	 available	 for	 analysis	 at	 the	 6‐
month	 assessment	 of	 CIPN	 (chosen	 as	 this	 point	 had	 the	 highest	
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TA B L E  1  Chemotherapy‐induced	peripheral	neuropathy	and	its	risk	factors	in	categorical	variables	(n	=	255)
Variable Frequency
Chemotherapy‐induced peripheral neuropathy (CIPN) frequency and percentage in each scale
CTCAE‐motor CTCAE‐sensory WHO item
Combined CIPN 
scales
Overall 255	(100%) 36	(14.1%) 33	(12.9%) 45	(17.6%) 68	(26.7%)
Race
Chinese 210	(82.4%) 30	(14.3%) 26	(12.4%) 34	(16.2%) 55	(26.2%)
Non‐Chinese	Asians 23	(9.0%) 3	(13.0%) 4	(17.4%) 9	(39.1%) 9	(39.1%)
Caucasian 22	(8.6%) 3	(13.6%) 3	(13.6%) 2	(9.1%) 4	(18.2%)
p‐value  0.98 0.79 0.01 0.26
Chemotherapy group
Taxanes 123	(48.2%) 25	(20.3%) 24	(19.5%) 30	(24.4%) 46	(37.4%)
Platinum 64	(25.1%) 4	(6.3%) 3	(4.7%) 6	(9.4%) 7	(10.9%)
Combined 68	(26.7%) 7	(10.3%) 6	(8.8%) 9	(13.2%) 15	(22.1%)
p‐value  0.02 0.008 0.02 <0.001
Treatment intent
Radical	(adjuvant) 157	(61.6%) 24	(15.3%) 19	(12.1%) 22	(14.0%) 39	(24.8%)
Radical	(neoadjuvant) 43	(16.9%) 6	(14.0%) 7	(16.3%) 10	(23.3%) 14	(32.6%)
Radical	(concurrent) 14	(5.5%) 1	(7.1%) 1	(7.1%) 0	(0.0%) 1	(7.1%)
Palliative 41	(16.1%) 5	(12.2%) 6	(14.6%) 13	(31.7%) 14	(34.1%)
p‐value  0.83 0.79 0.01 0.18
Chemotherapy protocol
Paclitaxel 27	(10.6%) 14	(51.9%) 15	(55.6%) 14	(51.9%) 15	(55.6%)
Docetaxel 96	(37.6%) 16	(16.7%) 31	(32.3%) 16	(16.7%) 31	(32.3%)
Cisplatin 41	(16.1%) 2	(4.9%) 3	(7.3%) 2	(4.9%) 3	(7.3%)
Oxaliplatin 20	(7.8%) 4	(20.0%) 4	(20.0%) 4	(20.0%) 4	(20.0%)
Carboplatin and 
docetaxel
28	(11.0%) 2	(7.1%) 3	(10.7%) 2	(7.1%) 3	(10.7%)
Carboplatin and 
paclitaxel
34	(13.3%) 7	(20.6%) 12	(35.3%) 7	(20.6%) 12	(35.3%)
p‐value  0.13 0.03 <0.001 <0.001
Diagnosis
Ovarian 25	(9.8%) 4	(16.0%) 4	(16.0%) 3	(12.0%) 7	(28.0%)
Lung 28	(11.0%) 1	(3.6%) 1	(3.6%) 1	(3.6%) 1	(3.6%)
Head	and	neck 17	(6.7%) 1	(5.9%) 1	(5.9%) 1	(5.9%) 2	(11.8%)
Breast 146	(57.3%) 25	(17.1%) 23	(15.8%) 32	(21.9%) 49	(33.6%)
Colorectal 15	(5.9%) 0	(0.0%) 0	(0.0%) 3	(20.0%) 0	(0.0%)
Others 24	(9.4%) 5	(20.8%) 4	(16.7%) 5	(20.8%) 5	(20.8%)
p‐value  0.15 0.25 0.15 0.02
Stage
I 41	(16.1%) 6	(14.6%) 5	(12.2%) 3	(7.3%) 9	(22.0%)
II 79	(31.0%) 14	(17.7%) 10	(12.7%) 17	(21.5%) 24	(30.4%)
III 84	(32.9%) 8	(9.5%) 9	(10.7%) 11	(13.1%) 18	(21.4%)
IV 51	(20.0%) 8	(15.7%) 9	(17.6%) 14	(27.5%) 17	(33.3%)
p‐value  0.49 0.71 0.04 0.34
Metronidazole 12	(4.7%) 3	(25.0%) 2	(16.7%) 3	(25.0%) 5	(41.7%)
p‐value  0.23 0.48 0.45 0.23
(Continues)
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CIPN	rate	and	highest	number	of	participants).	The	larger	study	had	
343	patients	at	baseline	and	2,399	observations	 in	 total,	although	
numbers decreased over time due to patients discontinuing chem‐
otherapy,	patient	death,	or	 relocation	of	patients.	There	were	162	





chemotherapy	 types	 (i.e.,	 docetaxel	 or	 cisplatin)	was	done	 initially	
separately,	 and	 as	 common	 risk	 factor	 patterns	 were	 observed	
across	protocols,	the	whole	data	was	subsequently	analyzed	and	re‐
ported together.
Non‐Chinese	Asians	 (primarily	 of	Malay	 and	 Indian	origin)	 had	
higher	 risk	of	 developing	neuropathy	 than	Chinese	or	Caucasians,	
only	when	the	WHO	scale	was	used	(p	=	0.01).	Also,	patients	receiv‐
ing	platinum‐based	chemotherapy	had	lower	risk	of	developing	CIPN	







statins was implicated in the development of sensory neuropathy 






in this group of patients. Detailed data are presented in Table 1.
Table 2 shows statistically significant predictors in contin‐
uous	 variables.	 Consistently	 (older)	 age	 and	 number	 of	 chemo‐
therapy	 cycles	 received	 were	 significant	 risk	 factors.	 Alcohol	
intake was significant only when the combined scale was used. 
Symptom	burden	 (mean	of	 all	 symptoms	 from	 the	EORTC	 scale)	
was	also	 linked	with	CIPN	 in	 this	univariate	analysis,	alongside	a	
number of symptoms in at least the combined CIPN scale. These 
included	 pain	 interfering	with	 daily	 activities	 (p	 =	 0.02),	 trouble	
sleeping	(p	=	0.04),	being	tired	(p	=	0.01),	appetite	loss	(p	=	0.04),	
constipation	 (p	 =	0.001),	worrying	 (p	 =	0.054),	 and	difficulty	 re‐
membering	(p	=	0.01).	Fruit	and	vegetable	intake	were	not	linked	
with	 CIPN.	 A	 stepwise	 logistic	 regression	 just	 for	 the	 individual	





variate predictors with p‐value	<	0.20	observed	in	the	previous	anal‐
yses	 showed	 that	 patients	 receiving	 platinum‐based	 chemotherapy	
had	 lower	 risk	 of	 CIPN	 compared	 to	 those	 receiving	 taxane‐based	
Variable Frequency
Chemotherapy‐induced peripheral neuropathy (CIPN) frequency and percentage in each scale
CTCAE‐motor CTCAE‐sensory WHO item
Combined CIPN 
scales
Statins 37	(14.5%) 7	(18.9%) 9	(24.3%) 9	(24.3%) 15	(40.5%)
p‐value  0.25 0.03 0.25 0.04
Gender
Male 49	(19.2%) 4	(8.2%) 3	(6.1%) 8	(16.3%) 9	(18.4%)
Female 206	(80.8%) 32	(15.5%) 30	(14.6%) 37	(18.0%) 59	(28.6%)
p‐value  0.18 0.11 0.79 0.14
Smoking history
Never 199	(78.0%) 29	(14.6%) 27	(13.6%) 36	(18.1%) 57	(28.6%)
Current 7	(2.7%) 1	(14.3%) 1	(14.3%) 3	(42.9%) 3	(42.9%)
Ex‐smoker 49	(19.2%) 6	(12.2%) 5	(10.2%) 6	(12.2%) 8	(16.3%)
p‐value  0.92 0.82 0.13 0.13
Diabetes 37	(14.5%) 5	(13.5%) 8	(21.6%) 7	(18.9%) 12	(32.4%)
p‐value  0.91 0.09 0.83 0.39
Hypothyroidism 6	(2.4%) 0	(0.0%) 0	(0.0%) 1	(16.7%) 1	(16.7%)
p‐value  0.40 0.43 0.71 0.58
History	of	neuropathy 13	(5.1%) 6	(46.2%) 4	(30.8%) 0	(0.0%) 6	(46.2%)
p‐value  0.001 0.049 0.09 0.10
Hepatitis	B	or	C 13	(5.1%) 1	(7.7%) 3	(23.1%) 4	(30.8%) 5	(38.5%)
p‐value  0.50 0.26 0.20 0.32
TA B L E  1   (Continued)
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chemotherapy; those with history of neuropathy had higher risk for 
(motor)	CIPN,	 as	well	 as	 older	 patients.	 Symptom	burden	had	 some	
contribution	to	(primarily	to	sensory)	CIPN.	Number	of	chemotherapy	
cycles received was also a strong predictor of CIPN. One unit of alcohol 
use	decreased	the	risk	of	CIPN	by	68%	(only	in	the	combined	scale).
7  | DISCUSSION
This study assessed CIPN clinical risk factors using a prospective 
design and a wide range of potential predictors. Overall CIPN in‐
cidence was lower in this study than that reported in the litera‐
ture,	and	this	has	to	do	probably	with	the	scales	used;	past	studies	
have	used	quality	of	life	scales	to	estimate	CIPN,	which	often	in‐
clude a range of general/broader items to indicate neuropathy. 
Also,	 clinician‐based	 assessments,	 such	 as	 the	NCI‐CTCAE	 tend	







this study due to the small number of events needing further clari‐
fication	 in	the	future)	and	number	of	chemotherapy	cycles	used.	
Patients	 receiving	 platinum‐based	 chemotherapy	 had	 17%–27%	
less	chance	of	developing	CIPN	compared	to	those	receiving	tax‐
ane‐based	chemotheraopy.	Risk	factors	were	not	always	consist‐
ent across the scales used. This may reflect sensitivity or reliability 









supporting	 findings	 from	 past	 research	 (Bandos	 et	 al.,	 2018;	
Hershman	et	al.,	2016;	Miaskowski	et	al.,	2017).	History	of	neu‐
ropathy was a potential risk factor for motor neuropathy and its 
ORs	were	high	in	the	other	CIPN	scales	(but	did	not	reach	statis‐
tical	 significance).	History	of	neuropathy	was	mainly	 linked	with	
motor	 CIPN,	with	 patients	 having	 such	 history	 being	more	 than	
eight times at a higher risk for developing motor CIPN. The limited 
research of the past does not differentiate the role of this variable 
in	the	type	of	neuropathy,	hence	this	is	a	novel	finding.	Statin	use	
as	a	risk	factor	for	CIPN	is	also	another	novel	finding	of	this	study,	
although this finding from univariate analysis was not sustained in 
the	final	model,	likely	because	of	the	small	number	of	patients	re‐
ceiving	statins	in	this	sample.	This	finding	supports	an	earlier	case‐
control	 study	on	patients	 receiving	 statins,	 although	 the	 sample	
in	 the	 latter	 study	was	not	 focusing	on	cancer	patients	 (Gaist	et	
al.,	2002).	However,	more	recent	work	from	a	case‐control	study	







Roach,	 &	 Donofrio,	 2006),	 although	 the	 small	 number	 of	 such	
cases may have contributed to the nonsignificant results shown. 
Such	 future	work	 should	 clearly	 delineate	 duration	 of	 use,	 dose	
and	timing	of	use,	which	were	not	collected	in	our	study	and	hence	
pose limitations in interpreting this result.
Symptom burden is a new variable implicated in the development 




difficulty remembering. It may be that neuronal damage related to 
CIPN leads to constipation or cognitive deficits in patients. The link 
between autonomic neuropathy and constipation may be the re‐
sult of neurogenic bowel/disautonomia or constipation may be one 
of the indications of constituent autonomic neuropathy. CIPN and 





understanding of the link between symptoms/symptom burden and 
CIPN. This finding is further supported by recent research showing 









may be associated with the development of neuropathy before the 
chemotherapy,	and	we	have	seen	that	preexisting	neuropathy	was	a	
key CIPN risk factor.
The number of chemotherapy cycles received was a strong pre‐
dictor both in univariate and multivariate analyses. This is not linked 
with	cumulative	dose	(as	the	latter	was	not	shown	to	be	predictive	
of	CIPN	in	our	study).	Hence,	this	finding	may	imply	that	“time”	after	
starting chemotherapy may be strongly linked with the development 
of	CIPN,	suggesting	that	CIPN	is	time‐dependent	rather	than	dose‐
dependent,	 although	 the	 link	 between	 cumulative	 dose	 and	CIPN	
has	been	reported	in	past	literature	but	not	consistently	(Seretny	et	
al.,	2014).
Two parameters in the final predictive model need some more 
consideration	in	the	development	of	CIPN.	Firstly,	the	role	of	hepa‐
titis	(possibly	as	a	result	of	taking	neurotoxic	antiviral	agents	in	the	
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past or even as a result of disturbance in the pharmacokinetics of the 
chemotherapy	drugs,	i.e.,	decreased	liver	function	and/or	increased	






for CIPN for hepatitis and smoking status.
Some	variables	in	the	study	had	small	frequency	counts,	and	this	
may	affect	the	interpretation	and	generalizability	of	the	results	and	
should be perceived as preliminary only. Identification of risk factors 








sity were not assessed in this study and these should be included in 
future models.
This	study	confirms	the	role	of	(older)	age;	number	of	chemo‐
therapy	cycles	 received,	and	 type	of	 chemotherapy	as	key	CIPN	
risk factors. The role of past neuropathic damage specifically 
linked	 with	 motor	 CIPN	 and	 (chronic)	 alcohol	 consumption	 are	
also important new variables to consider alongside the presence 
of symptom burden/specific symptoms that may form a symp‐
tom cluster around neuropathy. Risk factor knowledge can assist 
health professionals in educating patients in a more targeted way 
about	 this	 symptom	 experience	 and	 introduce	 more	 regular	 as‐
sessment	of	CIPN	particularly	 in	 those	at	higher	 risk,	 in	order	 to	
monitor its development and the impact it may have on patients’ 
quality	of	life.	Preventive	interventions	may	need	to	be	initiated	to	
those with high risk of CIPN.
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